Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 5/2010

01.09.2010

The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome

verfasst von: Christopher S. Gomez, Prashanth Kanagarajah, Angelo Gousse

Erschienen in: Current Urology Reports | Ausgabe 5/2010

Einloggen, um Zugang zu erhalten

Abstract

Overactive bladder syndrome continues to be a significant burden for the general population. Current first-line medical therapy often includes antimuscarinic medications designed for overactive bladder. Poor efficacy and significant side effects of these antimuscarinic medications have left patients and physicians looking for alternative treatments. There is increasing evidence that intradetrusor injection of botulinum toxin A can effectively treat these patients. We present a current and extensive review of the literature covering the use of botulinum toxin A in patients with overactive bladder with or without idiopathic detrusor overactivity.
Literatur
1.
Abrams P, Cardozo L, Fall M, et al.: The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167–178.CrossRefPubMed
2.
Stewart WF, Van Rooyen JB, Cundiff GW, et al.: Prevalence and burden of overactive bladder in the United States. World J Urol 2003, 20:327–336.PubMed
3.
Ganz ML, Smalarz AM, Krupski TL, et al.: Economic costs of overactive bladder in the United States. Urology 2010, 75:526–532, 532.e1–532.e18.CrossRefPubMed
4.
• Chapple C, De Ridder D: The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice? BJU Int 2009, 104:1188–1190. This article discusses the roles of various treatment options for overactive bladder.CrossRefPubMed
5.
• Chapple CR, Khullar V, Gabriel Z, et al.: The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008, 54:543–562. This article is an extensive meta-analysis on the efficacy of current antimuscarinics available to treat overactive bladder.CrossRefPubMed
6.
Novara G: Botulinum neurotoxin type A: the poison that can treat the sick. Eur Urol 2009, 55:560–562.CrossRefPubMed
7.
Erbguth FJ: From poison to remedy: the chequered history of botulinum toxin. J Neural Transm 2008, 115: 559–565.CrossRefPubMed
8.
Kuo HC: Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004, 63:868–872.CrossRefPubMed
9.
• Brubaker L, Richter HE, Visco A, et al.: Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008, 180:217–222. This randomized placebo controlled study was conducted to evaluate the efficacy of botulinum toxin A in OAB-wet patients.CrossRefPubMed
10.
• Cohen BL, Rivera R, Barboglio P, Gousse A: Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol 2007, 177:1006–1010. This article discusses the safe use of flexible cystoscopy for injecting botulinum toxin A.CrossRefPubMed
11.
• Flynn MK, Amundsen CL, Perevich M, et al.: Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol 2009, 181:2608–2615. This randomized controlled trial evaluated the use of botulinum toxin A.CrossRefPubMed
12.
Sahai A, Khan MS, Dasgupta P: Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007, 177:2231–2236.CrossRefPubMed
13.
• Khan S, Kessler TM, Apostolidis A, et al.: What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol 2009, 181:1773–1778. This initial report details the effect of repeat injections of botulinum toxin A.CrossRefPubMed
14.
Schmid DM, Sauermann P, Werner M, et al.: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006, 176:177–185.CrossRefPubMed
15.
Kuschel S, Werner M, Schmid DM, et al.: Botulinum toxin-A for idiopathic overactivity of the vesical detrusor: a 2-year follow-up. Int Urogynecol J Pelvic Floor Dysfunct 2008, 19:905–909.CrossRefPubMed
16.
Kuo HC: Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007, 178:1359–1363.CrossRefPubMed
17.
• Sahai A, Dowson C, Khan MS, et al.: Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010, 75:552–558. This is a report on dose optimization to improve voiding dysfunction after botulinum toxin A injection.CrossRefPubMed
18.
Chancellor MB: Ten years single surgeon experience with botulinum toxin in the urinary tract; clinical observations and research discovery. Int Urol Nephrol 2009 July 2 (Epub ahead of print).
19.
Giannantoni A, Rossi A, Mearini E, et al.: Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson’s disease and multiple system atrophy. J Urol 2009, 182:1453–1457.CrossRefPubMed
20.
Sahai A, Dowson C, Khan MS, Dasgupta P: Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009, 103:1509–1515.CrossRefPubMed
21.
• Cohen BL, Barboglio P, Rodriguez D, Gousse AE: Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units. Neurourol Urodyn 2009, 28:205–208. This initial report evaluates the optimal dose of botulinum toxin A for injection in patients with overactive bladder.CrossRefPubMed
22.
Jeffery S, Fynes M, Lee F, et al.: Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity. BJU Int 2007, 100:1302–1306.CrossRefPubMed
23.
Popat R, Apostolidis A, Kalsi V, et al.: A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005, 174:984–989.CrossRefPubMed
24.
Mohanty NK, Nayak RL, Alam M, Arora RP: Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience. Indian J Urol 2008, 24:182–185.CrossRefPubMed
25.
Khan S, Panicker J, Roosen A, et al.: Complete Continence after Botulinum Neurotoxin Type A Injections for Refractory Idiopathic Detrusor Overactivity Incontinence: Patient-Reported Outcome at 4 Weeks. Eur Urol 2009 April 21 (Epub ahead of print).
26.
Kalsi V, Apostolidis A, Popat R, et al.: Quality of life changes in patients with neurogenic versus idiopathic detrusor overactivity after intradetrusor injections of botulinum neurotoxin type A and correlations with lower urinary tract symptoms and urodynamic changes. Eur Urol 2006, 49:528–535.CrossRefPubMed
27.
Yablon SA, Brashear A, Gordon MF, et al.: Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007, 29:683–690.CrossRefPubMed
28.
29.
Digesu GA, Khullar V, Cardozo L, Salvatore S: Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003, 22:105–108. (Published erratum appears in Neurourol Urodyn 2003, 22:356.)CrossRefPubMed
30.
Dokmeci F, Seval M, Gok H: Comparison of ambulatory versus conventional urodynamics in females with urinary incontinence. Neurourol Urodyn 2010, 29:518–521.PubMed
31.
Gousse AE, Gomez CS, Kanagarajah P, et al.: Botox for idiopathic overactive bladder patients refractory to antimuscarinic therapy in the absence of urodynamically demonstrable detrusor overactivity. Neurourol Urodyn 2009, 28:107.CrossRef
32.
Sahai A, Khan MS, Le Gall N, et al.: Urodynamic assessment of poor responders after botulinum toxin-A treatment for overactive bladder. Urology 2008, 71:455–459.CrossRefPubMed
33.
Kessler TM, Khan S, Panicker J, et al.: Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol 2009, 113:1046–1051.PubMed
34.
De Laet K, Wyndaele JJ: Adverse events after botulinum A toxin injection for neurogenic voiding disorders. Spinal Cord 2005, 43:397–399.CrossRefPubMed
35.
Ruffion A, Capelle O, Paparel P, et al.: What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 2006, 97:1030–1034.CrossRefPubMed
36.
Adelson RT: Botulinum neurotoxins: fundamentals for the facial plastic surgeon. Am J Otolaryngol 2007, 28:260–266.CrossRefPubMed
Metadaten
Titel
The Use of Botulinum Toxin A in Idiopathic Overactive Bladder Syndrome
verfasst von
Christopher S. Gomez
Prashanth Kanagarajah
Angelo Gousse
Publikationsdatum
01.09.2010
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 5/2010
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-010-0134-4

Weitere Artikel der Ausgabe 5/2010

Current Urology Reports 5/2010 Zur Ausgabe

ReviewPaper

Can We Predict if Overactive Bladder Symptoms Will Resolve After Sling Surgery in Women With Mixed Urinary Incontinence?

ReviewPaper

Urodynamics in the Evaluation of Overactive Bladder

ReviewPaper

Sacral Nerve Modulation in Overactive Bladder

ReviewPaper

Should Asymptomatic Anterior Pelvic Organ Prolapse Be Corrected to Treat Irritative Urinary Symptoms?

ReviewPaper

Contrasting the Percutaneous Nerve Evaluation Versus Staged Implantation in Sacral Neuromodulation

ReviewPaper

The Impact of Urinary Incontinence and Its Treatment on Female Sexual Function

Neu im Fachgebiet Urologie

Schützt auch die medikamentöse Gewichtsreduktion vor Krebs?

03.06.2024 ASCO 2024 Kongressbericht

Offenbar muss es nicht immer die bariatrische Chirurgie sein, wenn es darum geht, durch deutlichen Gewichtsverlust auch das Krebsrisiko günstig zu beeinflussen. Eine große Kohortenanalyse zur Behandlung mit GLP-1-Agonisten wurde dazu auf der ASCO-Tagung vorgestellt.

Mit dem Seitenschneider gegen das Reißverschluss-Malheur

03.06.2024 Urologische Notfallmedizin Nachrichten

Wer ihn je erlebt hat, wird ihn nicht vergessen: den Schmerz, den die beim Öffnen oder Schließen des Reißverschlusses am Hosenschlitz eingeklemmte Haut am Penis oder Skrotum verursacht. Eine neue Methode für rasche Abhilfe hat ein US-Team getestet.

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise